GSK To Pay $92 Mil. To Settle Augmentin Antitrust Cases
This article was originally published in The Pink Sheet Daily
The company will reserve an additional $220 mil. to cover “certain other legal matters.” Charge to quarterly earnings will be offset by gains from equity investments and other income.
You may also be interested in...
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.